Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998179 | 0.86 | CHRM1 (0.38) | GRM5KDM4E | |
| SCHEMBL25519258 | 0.81 | GAA (0.33) | CDK2CCNE1GSK3BSMN1; SMN2 | |
| SCHEMBL19220264 | 0.81 | GAA (0.33) | CDK2CCNE1GSK3BSMN1; SMN2 | |
| SCHEMBL25519241 | 0.81 | CHRM2 (0.34) | TSHRKDM4E | |
| SCHEMBL19220263 | 0.81 | CHRM2 (0.34) | TSHRKDM4E | |
| SCHEMBL25519244 | 0.78 | KMT2A (0.41) | SMN1; SMN2TDP1 | |
| SCHEMBL25519256 | 0.77 | ACKR3 (0.36) | CDK2CCNE1HRH3GSK3B | |
| SCHEMBL19220286 | 0.77 | DRD3 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL25519260 | 0.76 | EPHX1 (0.36) | ALDH1A1 | |
| SCHEMBL25519257 | 0.75 | HSD11B1 (0.41) | HRH3TSHRKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655255-B2 | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein | SPH NO.1 BIOCHEMICAL & PHARMACEUTICAL CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655255-B2 | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein | SPH NO.1 BIOCHEMICAL & PHARMACEUTICAL CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655255-B2 | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein | PNP, TYMP, MTAP | CDK2 710/4885CCNE1 2379/4885GRM5 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.